Home Cart Sign in  
Chemical Structure| 5918-93-4 Chemical Structure| 5918-93-4

Structure of 5918-93-4

Chemical Structure| 5918-93-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 5918-93-4 ]

CAS No. :5918-93-4
Formula : C3H4N2O
M.W : 84.08
SMILES Code : O=C1NC=CN1
MDL No. :MFCD00040252
InChI Key :AICIYIDUYNFPRY-UHFFFAOYSA-N
Pubchem ID :22208

Safety of [ 5918-93-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 5918-93-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 6
Num. arom. heavy atoms 5
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 2.0
Molar Refractivity 21.41
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

48.65 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.63
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.86
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.3
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.08
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.42
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.04

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.44
Solubility 30.8 mg/ml ; 0.366 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.32
Solubility 175.0 mg/ml ; 2.09 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.03
Solubility 7.81 mg/ml ; 0.0929 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.42 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.0

Application In Synthesis of [ 5918-93-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 5918-93-4 ]

[ 5918-93-4 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 5918-93-4 ]
  • [ 1071-71-2 ]
  • 6-oxo-6-(2-oxo-2,3-dihydro-1<i>H</i>-imidazol-4-yl)-hexanoic acid [ No CAS ]
  • 3
  • [ 5918-93-4 ]
  • [ 98-88-4 ]
  • [ 77671-35-3 ]
YieldReaction ConditionsOperation in experiment
aluminium trichloride; In nitrobenzene; EXAMPLE 14 4-Benzoyl-1,3-dihydro-2H-imidazol-2-one To 51 ml of nitrobenzene is added 1.68 g of 1,3-dihydro-2H-imidazol-2-one, 5.3 g of aluminum chloride and 3.1 g of benzoyl chloride. The mixture is stirred for 3 hours at 60° C. and poured into ice water. The solids are filtered, washed with ether and recrystallized twice from methyl alcohol-water to afford the title compound. M.P. 329°-30° C.
  • 4
  • [ 5918-93-4 ]
  • [ 142-61-0 ]
  • [ 71647-94-4 ]
  • 5
  • [ 5918-93-4 ]
  • [ 109-94-4 ]
  • [ 72864-28-9 ]
  • 9
  • [ 623-33-6 ]
  • [ 5918-93-4 ]
  • 10
  • [ 5918-93-4 ]
  • [ 527-69-5 ]
  • [ 77671-36-4 ]
  • 11
  • [ 5918-93-4 ]
  • [ 5271-67-0 ]
  • [ 77681-44-8 ]
YieldReaction ConditionsOperation in experiment
aluminium trichloride; In nitrobenzene; EXAMPLE 13 1,3-Dihydro-4-(2-thienoyl)-2H-imidazol-2-one In 50 ml of nitrobenzene is combined 13.3 g of aluminum chloride, 4.2 g of 1,3-dihydro-2H-imidazol-2-one and 8.1 g of thienoyl chloride. The mixture is stirred at 60° C. for 3 hours and poured over ice water. The solids are filtered, washed with ether and recrystallized twice from ethanol-water to afford the title compound. M.P. 339°-42° C.
  • 12
  • [ 5918-93-4 ]
  • [ 1442-06-4 ]
  • [ 83167-14-0 ]
  • 14
  • [ 5918-93-4 ]
  • [ 100-07-2 ]
  • [ 83167-08-2 ]
  • 15
  • [ 5918-93-4 ]
  • [ 75-36-5 ]
  • [ 92635-44-4 ]
  • 16
  • [ 5918-93-4 ]
  • [ 999-97-3 ]
  • [ 80049-39-4 ]
  • 17
  • [ 5918-93-4 ]
  • [ 36239-09-5 ]
  • [ 107097-35-8 ]
  • 19
  • [ 5918-93-4 ]
  • [ 120-89-8 ]
  • 20
  • [ 5918-93-4 ]
  • [ 107292-24-0 ]
  • 22
  • [ 343864-63-1 ]
  • [ 5918-93-4 ]
  • 23
  • [ 116451-56-0 ]
  • [ 5918-93-4 ]
  • 26
  • [ 57-13-6 ]
  • anhydrous dioxylmaleic acid [ No CAS ]
  • [ 5918-93-4 ]
  • 27
  • [ 5918-93-4 ]
  • [ 7446-70-0 ]
  • [ 142-61-0 ]
  • [ 98-95-3 ]
  • [ 71647-94-4 ]
  • 28
  • [ 5918-93-4 ]
  • [ 154468-45-8 ]
  • [ 441045-33-6 ]
  • 29
  • [ 5918-93-4 ]
  • 1-chloro-2-deoxy-3,5-di-O-toluoyl-α-D-erythropentofuranose [ No CAS ]
  • 1-(2-deoxy-α-D-ribofuranosyl)imidazolin-2-one [ No CAS ]
  • [ 500778-10-9 ]
  • 30
  • [ 5918-93-4 ]
  • [ 589-87-7 ]
  • [ 6794-70-3 ]
  • 31
  • [ 5918-93-4 ]
  • [ 766-85-8 ]
  • 4-(3-methoxyphenyl)-1H-imidazol-2(3H)-one [ No CAS ]
  • 32
  • [ 5918-93-4 ]
  • [ 696-62-8 ]
  • [ 6794-72-5 ]
  • 33
  • [ 5918-93-4 ]
  • [ 5159-41-1 ]
  • 4-(2-(hydroxymethyl)phenyl)-1H-imidazol-2(3H)-one [ No CAS ]
  • 34
  • [ 5918-93-4 ]
  • [ 57455-06-8 ]
  • 4-(3-(hydroxymethyl)phenyl)-1H-imidazol-2(3H)-one [ No CAS ]
  • 35
  • [ 5918-93-4 ]
  • [ 540-38-5 ]
  • 4-(4-hydroxyphenyl)-1H-imidazol-2(3H)-one [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 5918-93-4 ]

Amides

Chemical Structure| 96-31-1

A190610 [96-31-1]

1,3-Dimethylurea

Similarity: 0.65

Chemical Structure| 598-50-5

A173396 [598-50-5]

1-Methylurea

Similarity: 0.60

Chemical Structure| 632-22-4

A727108 [632-22-4]

1,1,3,3-Tetramethylurea

Similarity: 0.57

Chemical Structure| 623-76-7

A146337 [623-76-7]

1,3-Diethylurea

Similarity: 0.52

Chemical Structure| 140-95-4

A426078 [140-95-4]

N,N'-Bis(hydroxymethyl)urea

Similarity: 0.52